Detecting heterozygous PVs in the MUTYH, NTHL1, MSH3, and MBD4 genes poses a clinical challenge for counseling monoallelic carriers about their cancer risk and for establishing rational surveillance protocols. The gene discussed is MBD4; the disease is cancer.